ALDX - AbbVie enters option deal for Aldeyra dry eye disease drug
2023-11-01 08:17:45 ET
More on AbbVie, Aldeyra Therapeutics, etc.
- AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results
- AbbVie Inc. (ABBV) Q3 2023 Earnings Call Transcript
- AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans
- AbbVie gains after Barclays upgrades over clarity on top-line evolution
- Needham says Abbvie's Botox sales results good news for Evolus, Revance
For further details see:
AbbVie enters option deal for Aldeyra dry eye disease drug